Anti-Human EGFR Recombinant Antibody (TAB-119) (CAT#: TAB-119)

Lu, Xinmiao, et al. "Radiolabeling and biological evaluation of 125 I-Necitumumab for EGFR-targeted SPECT imaging." Journal of Radioanalytical and Nuclear Chemistry 323 (2020): 83-89. https://doi.org/10.1007/s10967-019-06933-8

The study aimed to develop and evaluate a SPECT probe, 125I-Necitumumab, targeting the epidermal growth factor receptor (EGFR) for imaging non-small cell lung cancer (NSCLC). The researchers synthesized 125I-Necitumumab via the iodogen oxidation method and assessed its potential for SPECT imaging in vivo. The biodistribution study indicated rapid clearance of 125I-Necitumumab in most organs, with no significant uptake in tumor tissues despite the high EGFR expression. Consequently, the study concluded that 125I-Necitumumab is unsuitable for EGFR-targeted SPECT imaging of NSCLC.
Creative Biolabs provided the anti-human EGFR recombinant antibody Necitumumab (Cat#: TAB-119). The involvement of Creative Biolabs was crucial for obtaining the high-affinity EGFR-targeted antibody, enabling the researchers to synthesize the 125I-Necitumumab probe. This contribution facilitated the comprehensive evaluation of the probe's practicality for SPECT imaging, despite the final determination of its unsuitability for EGFR-targeted imaging in NSCLC.

Rasoulouniriana, Diana, et al. "T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors." Cancer Immunology Research 11.6 (2023): 792-809. https://doi.org/10.1158/2326-6066.CIR-22-0423

The study focused on engineering a modified FcgRI receptor for T cells, aiming to enhance their antibody-dependent cytotoxicity (ADCC) against solid tumors. This new receptor allows T cells to target tumor cells using antibodies, demonstrating effective and specific cytotoxicity only in the presence of appropriate antibodies. The engineered T cells, tested in both immunocompetent and immunodeficient mice, showed significant tumor eradication while secreting lower levels of cytokines compared to traditional CAR T cells, thus enhancing their safety profile. This technology offers a versatile approach, enabling the same engineered T cells to target different tumors by simply changing the injected antibody.
Creative Biolabs contributed by providing several critical antibodies for the study. Specifically, Creative Biolabs supplied Sofituzumab (Cat#: TAB-H63) and Necitumumab (Cat#: TAB-119). These antibodies were essential for testing the ADCC capabilities of the modified T cells, as they facilitated the targeting of specific tumor antigens, demonstrating the versatility and efficacy of the engineered T cells in preclinical models.